ADCs Targeting HER2+ Breast Cancer

Author(s):

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

EP: 1.Assessing HER2 Status Across Tumor Types

Please provide an overview of the evolution of ADCs in HER2+ breast cancer treatment.

Pembrolizumab Plus Bevacizumab/CAPOX Yields Responses in pMMR/MSS mCRC With High TILs

TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers

Nivolumab/Ipilimumab/Radiation Combo Produces Responses in Locally Advanced Rectal Cancer

Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status

Contact Info

2 Commerce Drive
Cranbury, NJ 08512